Correlation Between Verapamil Plasma Concentration and P-R Prolongation in Essential Hypertension
Plasma verapamil concentration was correlated with serial electrocardiographic P‐R intervals in patients with essential hypertension receiving immediate‐release (80 to 120 mg three times a day) or sustained‐release (240 mg daily) verapamil. The mean P‐R interval in 22 patients taking placebo and imm...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pharmacology 1988-09, Vol.28 (9), p.843-847 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 847 |
|---|---|
| container_issue | 9 |
| container_start_page | 843 |
| container_title | Journal of clinical pharmacology |
| container_volume | 28 |
| creator | Zachariah, Prince K. Shub, Clarence Sheps, Sheldon G. Schirger, Alexander Wolf, Mary K. Carlson, Christopher A. |
| description | Plasma verapamil concentration was correlated with serial electrocardiographic P‐R intervals in patients with essential hypertension receiving immediate‐release (80 to 120 mg three times a day) or sustained‐release (240 mg daily) verapamil. The mean P‐R interval in 22 patients taking placebo and immediate‐release verapamil was 0.18 second. The borderline first‐degree atrioventricular block of three patients did not change during treatment. Plasma verapamil concentrations of patients with a P‐R interval longer than 0.20 second and of those with a P‐R interval of 0.20 second or less were 169 ± 73 ng/mL and 63 ± 8 ng/mL, respectively. Six patients taking sustained‐release verapamil had a maximal mean P‐R interval of 0.19 ± 0.01 second during 24‐hour ambulatory electrocardiographic monitoring. P‐R intervals were 0.22 second or more in two patients, but they returned to normal by hour 7 for one and by hour 20 for the other patient. In summary, transient P‐R prolongation occurred with oral verapamil therapy, but no patient, regardless of baseline P‐R interval, developed high‐grade atrioventricular block. |
| doi_str_mv | 10.1002/j.1552-4604.1988.tb03226.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78686095</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78686095</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4386-d0b6d7c3f8c09f4c82e59a73dc4def10ebd3921b8f912f30f54e5850377f9afd3</originalsourceid><addsrcrecordid>eNqVkF2L1DAUhoMo67j6E4Qi4l3rSdL0wyvXsu4oy1pEd8GbkKYn0jFNx6TDzvx7W1rm3quEvM95T3gIeUMhoQDs_S6hQrA4zSBNaFkUydgAZyxLjk_I5hw9JRuAksYsB3hOXoSwA6BZKugFueCMAxV0Q1Q1eI9Wjd3gok84PiK66B692qu-s1FtVehVVA1Ooxv9ginXRnX8Par9YAf3e3nsXHQdwgR1ykbb0x79iC5MyUvyzCgb8NV6XpKfn69_VNv49tvNl-rqNtYpL7K4hSZrc81NoaE0qS4YilLlvNVpi4YCNi0vGW0KU1JmOBiRoigE8Dw3pTItvyTvlt69H_4eMIyy74JGa5XD4RBkXmRFBqWYwA8LqP0Qgkcj977rlT9JCnL2K3dylihniXL2K1e_8jgNv163HJoe2_PoKnTK3665ClpZ45XTXThjOecsTbMJ-7hgj53F0398QH6t6u18nSripaILIx7PFcr_kVnOcyEf7m7kPa0f7n7BVlb8HzUYqGo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78686095</pqid></control><display><type>article</type><title>Correlation Between Verapamil Plasma Concentration and P-R Prolongation in Essential Hypertension</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Zachariah, Prince K. ; Shub, Clarence ; Sheps, Sheldon G. ; Schirger, Alexander ; Wolf, Mary K. ; Carlson, Christopher A.</creator><creatorcontrib>Zachariah, Prince K. ; Shub, Clarence ; Sheps, Sheldon G. ; Schirger, Alexander ; Wolf, Mary K. ; Carlson, Christopher A.</creatorcontrib><description>Plasma verapamil concentration was correlated with serial electrocardiographic P‐R intervals in patients with essential hypertension receiving immediate‐release (80 to 120 mg three times a day) or sustained‐release (240 mg daily) verapamil. The mean P‐R interval in 22 patients taking placebo and immediate‐release verapamil was 0.18 second. The borderline first‐degree atrioventricular block of three patients did not change during treatment. Plasma verapamil concentrations of patients with a P‐R interval longer than 0.20 second and of those with a P‐R interval of 0.20 second or less were 169 ± 73 ng/mL and 63 ± 8 ng/mL, respectively. Six patients taking sustained‐release verapamil had a maximal mean P‐R interval of 0.19 ± 0.01 second during 24‐hour ambulatory electrocardiographic monitoring. P‐R intervals were 0.22 second or more in two patients, but they returned to normal by hour 7 for one and by hour 20 for the other patient. In summary, transient P‐R prolongation occurred with oral verapamil therapy, but no patient, regardless of baseline P‐R interval, developed high‐grade atrioventricular block.</description><identifier>ISSN: 0091-2700</identifier><identifier>EISSN: 1552-4604</identifier><identifier>DOI: 10.1002/j.1552-4604.1988.tb03226.x</identifier><identifier>PMID: 3230151</identifier><identifier>CODEN: JCPCBR</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Biological and medical sciences ; Delayed-Action Preparations ; Drug toxicity and drugs side effects treatment ; Electrocardiography ; Female ; Heart Rate - drug effects ; Humans ; Hypertension - blood ; Hypertension - drug therapy ; Hypertension - physiopathology ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Toxicity: cardiovascular system ; Verapamil - administration & dosage ; Verapamil - blood ; Verapamil - therapeutic use</subject><ispartof>Journal of clinical pharmacology, 1988-09, Vol.28 (9), p.843-847</ispartof><rights>1988 American College of Clinical Pharmacology</rights><rights>1989 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4386-d0b6d7c3f8c09f4c82e59a73dc4def10ebd3921b8f912f30f54e5850377f9afd3</citedby><cites>FETCH-LOGICAL-c4386-d0b6d7c3f8c09f4c82e59a73dc4def10ebd3921b8f912f30f54e5850377f9afd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fj.1552-4604.1988.tb03226.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fj.1552-4604.1988.tb03226.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7332446$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3230151$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zachariah, Prince K.</creatorcontrib><creatorcontrib>Shub, Clarence</creatorcontrib><creatorcontrib>Sheps, Sheldon G.</creatorcontrib><creatorcontrib>Schirger, Alexander</creatorcontrib><creatorcontrib>Wolf, Mary K.</creatorcontrib><creatorcontrib>Carlson, Christopher A.</creatorcontrib><title>Correlation Between Verapamil Plasma Concentration and P-R Prolongation in Essential Hypertension</title><title>Journal of clinical pharmacology</title><addtitle>J Clin Pharmacol</addtitle><description>Plasma verapamil concentration was correlated with serial electrocardiographic P‐R intervals in patients with essential hypertension receiving immediate‐release (80 to 120 mg three times a day) or sustained‐release (240 mg daily) verapamil. The mean P‐R interval in 22 patients taking placebo and immediate‐release verapamil was 0.18 second. The borderline first‐degree atrioventricular block of three patients did not change during treatment. Plasma verapamil concentrations of patients with a P‐R interval longer than 0.20 second and of those with a P‐R interval of 0.20 second or less were 169 ± 73 ng/mL and 63 ± 8 ng/mL, respectively. Six patients taking sustained‐release verapamil had a maximal mean P‐R interval of 0.19 ± 0.01 second during 24‐hour ambulatory electrocardiographic monitoring. P‐R intervals were 0.22 second or more in two patients, but they returned to normal by hour 7 for one and by hour 20 for the other patient. In summary, transient P‐R prolongation occurred with oral verapamil therapy, but no patient, regardless of baseline P‐R interval, developed high‐grade atrioventricular block.</description><subject>Biological and medical sciences</subject><subject>Delayed-Action Preparations</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Electrocardiography</subject><subject>Female</subject><subject>Heart Rate - drug effects</subject><subject>Humans</subject><subject>Hypertension - blood</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Toxicity: cardiovascular system</subject><subject>Verapamil - administration & dosage</subject><subject>Verapamil - blood</subject><subject>Verapamil - therapeutic use</subject><issn>0091-2700</issn><issn>1552-4604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkF2L1DAUhoMo67j6E4Qi4l3rSdL0wyvXsu4oy1pEd8GbkKYn0jFNx6TDzvx7W1rm3quEvM95T3gIeUMhoQDs_S6hQrA4zSBNaFkUydgAZyxLjk_I5hw9JRuAksYsB3hOXoSwA6BZKugFueCMAxV0Q1Q1eI9Wjd3gok84PiK66B692qu-s1FtVehVVA1Ooxv9ginXRnX8Par9YAf3e3nsXHQdwgR1ykbb0x79iC5MyUvyzCgb8NV6XpKfn69_VNv49tvNl-rqNtYpL7K4hSZrc81NoaE0qS4YilLlvNVpi4YCNi0vGW0KU1JmOBiRoigE8Dw3pTItvyTvlt69H_4eMIyy74JGa5XD4RBkXmRFBqWYwA8LqP0Qgkcj977rlT9JCnL2K3dylihniXL2K1e_8jgNv163HJoe2_PoKnTK3665ClpZ45XTXThjOecsTbMJ-7hgj53F0398QH6t6u18nSripaILIx7PFcr_kVnOcyEf7m7kPa0f7n7BVlb8HzUYqGo</recordid><startdate>198809</startdate><enddate>198809</enddate><creator>Zachariah, Prince K.</creator><creator>Shub, Clarence</creator><creator>Sheps, Sheldon G.</creator><creator>Schirger, Alexander</creator><creator>Wolf, Mary K.</creator><creator>Carlson, Christopher A.</creator><general>Blackwell Publishing Ltd</general><general>Sage Science</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198809</creationdate><title>Correlation Between Verapamil Plasma Concentration and P-R Prolongation in Essential Hypertension</title><author>Zachariah, Prince K. ; Shub, Clarence ; Sheps, Sheldon G. ; Schirger, Alexander ; Wolf, Mary K. ; Carlson, Christopher A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4386-d0b6d7c3f8c09f4c82e59a73dc4def10ebd3921b8f912f30f54e5850377f9afd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Biological and medical sciences</topic><topic>Delayed-Action Preparations</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Electrocardiography</topic><topic>Female</topic><topic>Heart Rate - drug effects</topic><topic>Humans</topic><topic>Hypertension - blood</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Toxicity: cardiovascular system</topic><topic>Verapamil - administration & dosage</topic><topic>Verapamil - blood</topic><topic>Verapamil - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zachariah, Prince K.</creatorcontrib><creatorcontrib>Shub, Clarence</creatorcontrib><creatorcontrib>Sheps, Sheldon G.</creatorcontrib><creatorcontrib>Schirger, Alexander</creatorcontrib><creatorcontrib>Wolf, Mary K.</creatorcontrib><creatorcontrib>Carlson, Christopher A.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zachariah, Prince K.</au><au>Shub, Clarence</au><au>Sheps, Sheldon G.</au><au>Schirger, Alexander</au><au>Wolf, Mary K.</au><au>Carlson, Christopher A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlation Between Verapamil Plasma Concentration and P-R Prolongation in Essential Hypertension</atitle><jtitle>Journal of clinical pharmacology</jtitle><addtitle>J Clin Pharmacol</addtitle><date>1988-09</date><risdate>1988</risdate><volume>28</volume><issue>9</issue><spage>843</spage><epage>847</epage><pages>843-847</pages><issn>0091-2700</issn><eissn>1552-4604</eissn><coden>JCPCBR</coden><abstract>Plasma verapamil concentration was correlated with serial electrocardiographic P‐R intervals in patients with essential hypertension receiving immediate‐release (80 to 120 mg three times a day) or sustained‐release (240 mg daily) verapamil. The mean P‐R interval in 22 patients taking placebo and immediate‐release verapamil was 0.18 second. The borderline first‐degree atrioventricular block of three patients did not change during treatment. Plasma verapamil concentrations of patients with a P‐R interval longer than 0.20 second and of those with a P‐R interval of 0.20 second or less were 169 ± 73 ng/mL and 63 ± 8 ng/mL, respectively. Six patients taking sustained‐release verapamil had a maximal mean P‐R interval of 0.19 ± 0.01 second during 24‐hour ambulatory electrocardiographic monitoring. P‐R intervals were 0.22 second or more in two patients, but they returned to normal by hour 7 for one and by hour 20 for the other patient. In summary, transient P‐R prolongation occurred with oral verapamil therapy, but no patient, regardless of baseline P‐R interval, developed high‐grade atrioventricular block.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>3230151</pmid><doi>10.1002/j.1552-4604.1988.tb03226.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-2700 |
| ispartof | Journal of clinical pharmacology, 1988-09, Vol.28 (9), p.843-847 |
| issn | 0091-2700 1552-4604 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78686095 |
| source | MEDLINE; Wiley Journals |
| subjects | Biological and medical sciences Delayed-Action Preparations Drug toxicity and drugs side effects treatment Electrocardiography Female Heart Rate - drug effects Humans Hypertension - blood Hypertension - drug therapy Hypertension - physiopathology Male Medical sciences Middle Aged Pharmacology. Drug treatments Toxicity: cardiovascular system Verapamil - administration & dosage Verapamil - blood Verapamil - therapeutic use |
| title | Correlation Between Verapamil Plasma Concentration and P-R Prolongation in Essential Hypertension |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T04%3A03%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlation%20Between%20Verapamil%20Plasma%20Concentration%20and%20P-R%20Prolongation%20in%20Essential%20Hypertension&rft.jtitle=Journal%20of%20clinical%20pharmacology&rft.au=Zachariah,%20Prince%20K.&rft.date=1988-09&rft.volume=28&rft.issue=9&rft.spage=843&rft.epage=847&rft.pages=843-847&rft.issn=0091-2700&rft.eissn=1552-4604&rft.coden=JCPCBR&rft_id=info:doi/10.1002/j.1552-4604.1988.tb03226.x&rft_dat=%3Cproquest_cross%3E78686095%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78686095&rft_id=info:pmid/3230151&rfr_iscdi=true |